Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen S Messer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Breast Cancer Research : BCR|October 16, 2015
Multipotent luminal mammary cancer stem cells model tumor heterogeneityLei Bao, Robert D Cardiff, Paul Steinbach, et al.
ACS Nano|March 24, 2018
Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient BloodJean M Lewis, Ankit D Vyas, Yuqi Qiu, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|February 28, 2009
Intermittent and light daily smoking across racial/ethnic groups in the United StatesDennis R Trinidad, Eliseo J Pérez-Stable, Sherry L Emery, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF AlterationsShawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF AlterationsShawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
Journal of the American College of Surgeons|May 29, 2012
Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse modelsCristina A Metildi, Sharmeela Kaushal, Chanae R Hardamon, et al.
JCI Insight|September 22, 2017
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancerFumi Sato-Kaneko, Shiyin Yao, Alast Ahmadi, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Nature|December 16, 2016
Corrigendum: PI3Kγ is a molecular switch that controls immune suppressionMegan M Kaneda, Karen S Messer, Natacha Ralainirina, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Breast Cancer Research : BCR|October 16, 2015
Multipotent luminal mammary cancer stem cells model tumor heterogeneityLei Bao, Robert D Cardiff, Paul Steinbach, et al.
ACS Nano|March 24, 2018
Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient BloodJean M Lewis, Ankit D Vyas, Yuqi Qiu, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|February 28, 2009
Intermittent and light daily smoking across racial/ethnic groups in the United StatesDennis R Trinidad, Eliseo J Pérez-Stable, Sherry L Emery, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF AlterationsShawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF AlterationsShawn Alaron Abeynaike, Roberta Vezza Alexander, Christina Snider, et al.
Journal of the American College of Surgeons|May 29, 2012
Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse modelsCristina A Metildi, Sharmeela Kaushal, Chanae R Hardamon, et al.
JCI Insight|September 22, 2017
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancerFumi Sato-Kaneko, Shiyin Yao, Alast Ahmadi, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Nature|December 16, 2016
Corrigendum: PI3Kγ is a molecular switch that controls immune suppressionMegan M Kaneda, Karen S Messer, Natacha Ralainirina, et al.
Pageof 2